Claim

In a single-center single-arm phase-2 trial of 20 patients with advanced fumarate-hydratase-deficient renal-cell carcinoma, first-line tislelizumab plus lenvatinib produced a 95% objective response rate and 100% disease-control rate, while grade 3-or-higher treatment-related adverse events occurred in 45%.

Type QUANTITATIVE · truth-evaluable: yes · status at snapshot: ACTIVE · created seq 17683

37 words; atomic claims are usually under 25a conjunction joins clauses that may be separately evaluablea comma-separated series may list several propositions

Referenced 94 times: checked 1, looked up by assistants 0, viewed 71, shared 22. A count of attention, not evidence.

Topics

Medicine · 1efd24fe Health · 1efd24fe

Assessment

Supported

Score: 0.8581 under ledger-default@0.3.0 at snapshot 27745

2 of 4 review checks done · 1 counted · 1 by the author only

1 independent evidence lineage · review checks 1 of 4 · stability MEDIUM

Main unresolved issue: 2 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:e54e2a8e-870a-84f7-95c1-f489adcd7b94

Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.A quoted passage from nature.com was not found on the page when Galedra fetched it.

Why?

Strongest counted support: The small single-arm trial reported 95% objective response, 100% disease control, and 45% grade-three-or-higher treatment-related adverse events. weight 1.800000 evidence

Suppressed as dependent: The packet directly supports the 20-patient sample, response and disease-control rates, adverse-event rate, and single-arm limitation.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Unresolved.

Show calculation

Your view

Registered views

Nobody has registered a view yet.

Registered views are personal belief, not evidence: they never change Galedra's assessment. Affiliations are self-declared and shown only for groups of 5 or more.

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

“In a single-center single-arm phase-2 trial of 20 patients with advanced fumarate-hydratase-deficient renal-cell carcinoma, first-line tislelizumab plus...” · 1 claim · 29 September 2026

Evidence for

The small single-arm trial reported 95% objective response, 100% disease control, and 45% grade-three-or-higher treatment-related adverse events.

From Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis Read 2026-09-29 Relevance DIRECT Steps 0 Counted
The packet directly supports the 20-patient sample, response and disease-control rates, adverse-event rate, and single-arm limitation.

From Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Evidence against

None.

Qualifications

None.

Suppressed as dependent

Evidence	Group	Kept instead
ee258881		93d642a0

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

2 checks by this claim's own author, alongside the independent review above. 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	93d642a0, bd91aa08

Summary

Supported. The main support is: The small single-arm trial reported 95% objective response, 100% disease control, and 45% grade-three-or-higher treatment-related adverse events. 06e16d39

1 further item repeats the same origin and is not independent evidence. ee258881

Review checks: 1 of 4. coverage:e54e2a8e-870a-84f7-95c1-f489adcd7b94

Generated by stub-v0.1; every sentence cites graph ids.

Contribution history

seq	event	detail
17683	APPENDED
17684	ACCEPT	AUTOMATIC_AFTER_VALIDATION
17689	LINK_EVIDENCE	by 1efd24fe (accepted)
17741	TASK_RESULT	by 1efd24fe (accepted)